- Wilding JP, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine; February 10, 2021. Accessed February 18, 2021. doi: 10.1056/NEJMoa2032183.
A recent study published in The New England Journal of Medicine reported that treatment with once weekly semaglutide, along with lifestyle intervention, in individuals who are overweight or obese resulted in sustained and clinically beneficial weight loss.
Obesity is a chronic disease that can lead to insulin resistance, hypertension, and dyslipidemia and is associated with type 2 diabetes and cardiovascular disease (CVD), among other conditions. Despite the prevalence of obesity worldwide, there remain few drugs indicated for the disease.
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved to treat type 2 diabetes and to reduce the risk of cardiovascular events in individuals with type 2 diabetes and CVD.
Read the full article on Drug Topics here: https://www.drugtopics.com/view/study-shows-clinical-benefit-with-once-weekly-semaglutide-in-patients-with-obesity